EDITAS MEDICINE INC (EDIT) Stock News

USA - NASDAQ:EDIT - US28106W1036 - Common Stock

3.72 USD

+0.07 (+1.92%)

Last: 10/24/2025, 8:20:34 PM

3.7584 USD

+0.04 (+1.03%)

After Hours: 10/24/2025, 8:20:34 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EDIT Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Chartmill

News Image

Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend

17 days ago - By: Editas Medicine, Inc.

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

17 days ago - By: Editas Medicine, Inc.

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

20 days ago - By: Editas Medicine, Inc.

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

20 days ago - By: Editas Medicine, Inc.

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

a month ago - By: Benzinga - Mentions: ILMN VRTX LLY NVO ...

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

2 months ago - By: Benzinga

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

2 months ago - By: Zacks Investment Research - Mentions: CRMD KNSA PHAR

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

2 months ago - By: Editas Medicine, Inc.

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

2 months ago - By: Editas Medicine, Inc.

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

2 months ago - By: Editas Medicine, Inc.

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

2 months ago - By: Editas Medicine, Inc.

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

2 months ago - By: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

2 months ago - By: Editas Medicine, Inc.

Editas Medicine to Participate in Upcoming Investor Conferences

3 months ago - By: Zacks Investment Research - Mentions: DARE

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

3 months ago - By: Editas Medicine, Inc.

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

3 months ago - By: Zacks Investment Research - Mentions: TCRX

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: HUMA

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: The Motley Fool - Mentions: SRPT

2 Beaten-Down Stocks to Avoid

4 months ago - By: Yahoo Finance - Mentions: WWD NTLA BAC

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

4 months ago - By: The Motley Fool

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

4 months ago - By: Investor's Business Daily - Mentions: LLY VERV NTLA CRSP ...

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

5 months ago - By: Editas Medicine, Inc.

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

5 months ago - By: Editas Medicine, Inc.

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

5 months ago - By: Yahoo Finance - Mentions: BAC O EPD LMT ...

1 Stock Down 97% That Could Double, According to Wall Street

5 months ago - By: Yahoo Finance - Mentions: TSM O AAPL AMZN ...

4 Reasons to Buy Taiwan Semiconductor Manufacturing Stock Like There's No Tomorrow